Ocumension’s OT-703 Approved for Study in Hainan

Ocumension Therapeutics ( (HK:1477) ) just unveiled an announcement.

Ocumension Therapeutics announced that its product OT-703, an injectable fluocinolone intravitreal implant for diabetic macular edema, has been approved for a real-world study in Hainan, China. This approval marks a significant step in the company’s efforts to expand its presence in the Asian market, following its exclusive licensing agreement with Alimera Sciences for the development and commercialization of ILUVIEN in Greater China and other regions.

The most recent analyst rating on (HK:1477) stock is a Buy with a HK$7.29 price target. To see the full list of analyst forecasts on Ocumension Therapeutics stock, see the HK:1477 Stock Forecast page.

More about Ocumension Therapeutics

Ocumension Therapeutics is a company incorporated in the Cayman Islands, focusing on the development and commercialization of ophthalmic products. The company has a market focus on Greater China, South Korea, and Southeast Asia, with a particular emphasis on treatments for diabetic macular edema.

Average Trading Volume: 3,365,075

Technical Sentiment Signal: Hold

Current Market Cap: HK$4.27B

See more data about 1477 stock on TipRanks’ Stock Analysis page.